4 February 2010

Apeiron signs £207M deal with Glaxo

Science|Business

Licensing

Apeiron Biologics AG has granted GlaxoSmithKline plc (GSK) exclusive rights to APN01, a recombinant form of human Angiotensin Converting Enzyme 2, (rhACE2) for treating Acute Respiratory Distress Syndrome (ARDS), in a deal with a possible value of £207 million. Apeiron will receive an up-front payment of £11 million in cash and equity investment, and will receive royalties on net sales.

Hans Loibner, CEO of Apeiron, said, “We are very pleased that we could attract GSK, one of the world's top pharmaceutical companies, to license this exciting project. I am convinced that Apeiron’s know-how in this area, together with the extensive development and marketing capabilities of GSK, are the best way forward to bring an innovative therapy to patients...

This page requires a subscription

This page is available to subscribers only. Please log in or subscribe and plug into the Science|Buisiness Network now, to get full access to all our news, events, business opportunities and subscriber-posting service.

We are the first independent news service connecting buyers and sellers of emerging technologies, across borders and across industries. We keep you ahead of the news on early-stage R&D investment – and provide opportunities for you to find and meet new investors, licensees and development partners, through our unique Science|Business Network of leading scientific institutions including the University of Cambridge, Karolinska Institute, ETH-Zürich and Imperial College London.

Be first into the next wave of technology. Click here to learn more

Note: Log in requires cookies to be enabled on your machine.

Lost your password? Enter your email address with no password and we'll send you a new password. Use this to log in, then, if you wish, click on the 'My Details' link at the top of the page to change your password.